Thomas September 8, 2004 Der nächste gepushte Schrott? :-" 20.08.2004 Biophan Reaches Major Milestone in Intellectual Property; Expands Biomedical Technology Portfolio to Total of 80 Patents, Licenses or Applications Biophan Reaches Major Milestone in Intellectual Property; Expands Biomedical Technology Portfolio to Total of 80 Patents, Licenses or Applications BW5367 AUG 20,2004 13:02 PACIFIC 16:02 EASTERN ( BW)(NY-BIOPHAN-TECHNOLOGIES)(BIPH) Biophan Reaches Major Milestonein Intellectual Property; Expands Biomedical Technology Portfolio toTotal of 80 Patents, Licenses or Applications Business Editors/Health/Medical Writers ROCHESTER, N.Y.--(BUSINESS WIRE)--Aug. 20, 2004-- Count Represents 30% Growth of Technology Portfolio in 2nd Quarter Biophan Technologies, Inc. (OTC BB: BIPH), a developer ofnext-generation biomedical technology, today announced that thecompany´s technology portfolio has swelled to 80 different patents,and pending patent applications either owned by Biophan or itslicensors. The portfolio of groundbreaking technologies represents theworld´s most significant collection of intellectual property focusedupon extending the safety, functionality, and compatibility of vitalbiomedical devices with magnetic resonance imaging (MRI), one ofmedicine´s most important diagnostic imaging tools. The announcementwas made by Michael Weiner, president and CEO of Biophan. The Company has expanded its advanced technology portfolio 30% inthe last 3 months alone, and the steep rate of technology acquisitionis continuing. Biophan´s patents and licenses involve severalcutting-edge fields of research and development, includingnanotechnology and biothermal battery technology. "The future and success of Biophan lies in the commercializationof critically important and far-reaching science and technology.Biophan is at the forefront of this development," said Mr. Weiner. "Itis extraordinary that we have been able to amass so much cutting-edgetechnology in such a short time, and we are excited by the vast marketopportunities available for the products we´re developing with thisworld-class portfolio of intellectual property." Our technology hasthe potential to impact millions of lives as biomedical devices aremade safe for use with MRI, or are powered by biothermal batteries, orenhanced by drug delivery innovations. Biophan recently announced a joint development agreement with theNASA Ames Research Center for Nanotechnology, Moffet Field, CA, forthe characterization and development of high-density, nano-engineeredthermoelectric materials for use with implantable medical devices. Formore investor-specific information about Biophan, or to view streamingvideo of Biophan´s Michael Weiner and NASA´s David Lackner announcingthe agreement, go to Trilogy Capital´s homepage atwww.trilogy-capital.com. About Biophan Technologies Biophan Technologies develops and markets cutting-edgetechnologies designed to make biomedical devices safe and compatiblewith magnetic resonance imaging (MRI) equipment. The Company developsenabling technologies for implanted medical systems such aspacemakers, and interventional surgical devices such as catheters andguidewires, as well as stents and other implants that can be safelyand effectively imaged under MRI. The technology is also being used tocreate enhanced MRI contrast agents. Committed to growth throughinnovation and developmental leadership, Biophan and its licensorshave 19 issued U.S. patents and 61 patents pending, in areas includingnanotechnology (nanomagnetic particle coatings), radio frequencyfilters, polymer composites, biothermal batteries, and photonics.Biophan´s technology will help realize its goal of one day making allbiomedical devices capable of safely and successfully working withMRI. For more information, please visit www.biophan.com. Cautionary Statement Regarding Forward-Looking Statements Certain statements included in this press release may constituteforward-looking statements. Actual results could differ materiallyfrom such statements expressed or implied herein as a result of avariety of factors including, but not limited to: the development ofBiophan´s MRI technologies; the approval of Biophan´s patentapplications; the successful implementation of Biophan´s research anddevelopment programs; the acceptance by the market of Biophan´sproducts; competition and the timing of projects and trends in futureoperating performance, as well as other factors expressed from time totime in Biophan´s periodic filings with the Securities and ExchangeCommission (the "SEC"). As a result, this press release should be readin conjunction with Biophan´s periodic filings with the SEC. Theforward-looking statements contained herein are made only as of thedate of this press release, and Biophan undertakes no obligation topublicly update such forward-looking statements to reflect subsequentevents or circumstances. --30--AC/ny* CONTACT: Biophan Technologies, Inc. Carolyn Hotchkiss, 585-214-2407 or Press Interviews: Michael Weiner, 585-214-2441 KEYWORD: NEW YORK INDUSTRY KEYWORD: BANKING MEDICAL DEVICES MEDICAL BIOTECHNOLOGY SOURCE: Biophan Technologies, Inc. © 2004 Business Wire. All reproduction, other than for an individual user`s reference, is prohibited without prior written permission. Diesen Beitrag teilen Link zum Beitrag
Graslunge September 29, 2004 und, was wird hier so von diesem Wert gehalten?? Diesen Beitrag teilen Link zum Beitrag
Prometheus September 29, 2004 Halte das Konzept für nicht sehr ausgereift - für mich keinen zweiten Blick wert. Diesen Beitrag teilen Link zum Beitrag
Thomas September 29, 2004 Jep, was ich mit "gepushter Schrott" meinte. Diesen Beitrag teilen Link zum Beitrag
Thomas Oktober 15, 2004 Ich sollte auch öfters mal auf gepushten Schrott setzen, mittlerweile steht Biophan bei 0,96! Und das troz des aktuellen Marktumfeldes. Als ich das Thema hier öffnete, waren es nur 0,62 Naja ... man lernt dazu :laugh: :laugh: :laugh: Diesen Beitrag teilen Link zum Beitrag
